Seth Celina, Schmid Veronika, Mueller Stephan, Haykowsky Mark, Foulkes Stephen J, Halle Martin, Wernhart Simon
Department for Preventive Sports Medicine and Sports Cardiology, Technical University of Munich, Georg-Brauchle-Ring 56/58, 80992, Munich, Germany.
School of Medicine and Health, TUM University Hospital, Munich, Germany.
Herz. 2025 Mar 14. doi: 10.1007/s00059-025-05309-x.
Diabetes, obesity, and cardiovascular disease (CVD) represent an escalating global health challenge, contributing significantly to morbidity, mortality, and healthcare costs. Evidence from large cohort studies and clinical trials underscores the impact of diabetes and obesity as major risk factors for CVD, causing systemic inflammation, insulin resistance, and neurohormonal activation. Frequently, a sedentary lifestyle and unbalanced dietary habits are associated with these risk factors. Physical activity and exercise training interventions, a Mediterranean and plant-based diet, smoking cessation, and reduction of alcohol have shown promise in mitigating these risks. The implementation of lifestyle and pharmacotherapy have emerged as new pillars of preventive medicine. This review discusses the evidence of lifestyle interventions to reduce the burden of diabetes, obesity, and CVD. It is highlighted that only a multifaceted, sustained approach integrating lifestyle interventions and pharmacological strategies can reduce the burden of disease and improve long-term outcomes.
糖尿病、肥胖症和心血管疾病(CVD)是日益严峻的全球健康挑战,对发病率、死亡率和医疗成本有重大影响。大型队列研究和临床试验的证据强调了糖尿病和肥胖症作为心血管疾病主要危险因素的影响,会导致全身炎症、胰岛素抵抗和神经激素激活。通常,久坐不动的生活方式和不均衡的饮食习惯与这些危险因素相关。体育活动和运动训练干预、地中海饮食和植物性饮食、戒烟以及减少饮酒已显示出减轻这些风险的前景。生活方式干预和药物治疗的实施已成为预防医学的新支柱。本综述讨论了生活方式干预以减轻糖尿病、肥胖症和心血管疾病负担的证据。需要强调的是,只有将生活方式干预和药物治疗策略相结合的多方面、持续的方法才能减轻疾病负担并改善长期预后。